Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO ...
| KURA Stock | USD 6.36 0.04 0.63% |
About 51% of Kura Oncology's investor base is interested to short. The analysis of overall sentiment of trading Kura Oncology stock suggests that many investors are impartial at this time. The current market sentiment, together with Kura Oncology's historical and current headlines, can help investors time the market. In addition, many technical investors use Kura Oncology stock news signals to limit their universe of possible portfolio assets.
Ziftomenib achieved a 23 percent complete remission rate in a Phase 2 trial for NPM1-mutated AML. 63 percent of evaluable patients achieving CRCRh reached MRD-negati
Read at gurufocus.com
 |
Kura Oncology Fundamental Analysis
We analyze Kura Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kura Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kura Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
Kura Oncology is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Kura Oncology Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kura Oncology stock to make a market-neutral strategy. Peer analysis of Kura Oncology could also be used in its relative valuation, which is a method of valuing Kura Oncology by comparing valuation metrics with similar companies.
Peers
Kura Oncology Related Equities
| SNDX | Syndax Pharmaceuticals | 21.10 | ||||
| COGT | Cogent Biosciences | 5.70 | ||||
| MRSN | Mersana Therapeutics | 2.62 | ||||
| CGEM | Cullinan Oncology | 1.76 | ||||
| KALV | Kalvista Pharmaceuticals | 0.76 | ||||
| ANAB | AnaptysBio | 1.86 |
Complementary Tools for Kura Stock analysis
When running Kura Oncology's price analysis, check to measure Kura Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kura Oncology is operating at the current time. Most of Kura Oncology's value examination focuses on studying past and present price action to predict the probability of Kura Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kura Oncology's price. Additionally, you may evaluate how the addition of Kura Oncology to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |